244 related articles for article (PubMed ID: 28359080)
21. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
22. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
[TBL] [Abstract][Full Text] [Related]
23. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
24. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
[TBL] [Abstract][Full Text] [Related]
25. NFAT-1 hyper-activation by methionine enkephalin (MENK) significantly induces cell apoptosis of rats C6 glioma in vivo and in vitro.
Lu WC; Xie H; Tie XX; Wang R; Wu AH; Shan FP
Int Immunopharmacol; 2018 Mar; 56():1-8. PubMed ID: 29324390
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
27. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.
Zhang WB; Wang Z; Shu F; Jin YH; Liu HY; Wang QJ; Yang Y
J Biol Chem; 2010 Dec; 285(52):40461-71. PubMed ID: 20880848
[TBL] [Abstract][Full Text] [Related]
28. MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Song Y; Zhang L; Jiang Y; Hu T; Zhang D; Qiao Q; Wang R; Wang M; Han S
Theranostics; 2019; 9(20):6019-6030. PubMed ID: 31534534
[No Abstract] [Full Text] [Related]
29. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
Wagner L; Marschall V; Karl S; Cristofanon S; Zobel K; Deshayes K; Vucic D; Debatin KM; Fulda S
Oncogene; 2013 Feb; 32(8):988-97. PubMed ID: 22469979
[TBL] [Abstract][Full Text] [Related]
30. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Liu YJ; Ma YC; Zhang WJ; Yang ZZ; Liang DS; Wu ZF; Qi XR
Oncotarget; 2017 Jun; 8(26):42495-42509. PubMed ID: 28477008
[TBL] [Abstract][Full Text] [Related]
32. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S
Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
[TBL] [Abstract][Full Text] [Related]
34. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
35. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
36. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
37. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
38. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK
Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257
[TBL] [Abstract][Full Text] [Related]
40. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]